Araghi, A, Taghizadeh, M, Hosseini Doust, S. R, Paradise, A, Azimi Dezfouli, S. M. (1402). Evaluation of Immunogenicity of Clostridium perfringens Type B Toxoid and Inactivated FMD (O) Virus with Adjuvant (ISA70-MF59). سامانه مدیریت نشریات علمی, 78(3), 907-913. doi: 10.22092/ari.2022.360215.2565
A Araghi; M Taghizadeh; S. R Hosseini Doust; A Paradise; S. M Azimi Dezfouli. "Evaluation of Immunogenicity of Clostridium perfringens Type B Toxoid and Inactivated FMD (O) Virus with Adjuvant (ISA70-MF59)". سامانه مدیریت نشریات علمی, 78, 3, 1402, 907-913. doi: 10.22092/ari.2022.360215.2565
Araghi, A, Taghizadeh, M, Hosseini Doust, S. R, Paradise, A, Azimi Dezfouli, S. M. (1402). 'Evaluation of Immunogenicity of Clostridium perfringens Type B Toxoid and Inactivated FMD (O) Virus with Adjuvant (ISA70-MF59)', سامانه مدیریت نشریات علمی, 78(3), pp. 907-913. doi: 10.22092/ari.2022.360215.2565
Araghi, A, Taghizadeh, M, Hosseini Doust, S. R, Paradise, A, Azimi Dezfouli, S. M. Evaluation of Immunogenicity of Clostridium perfringens Type B Toxoid and Inactivated FMD (O) Virus with Adjuvant (ISA70-MF59). سامانه مدیریت نشریات علمی, 1402; 78(3): 907-913. doi: 10.22092/ari.2022.360215.2565
Evaluation of Immunogenicity of Clostridium perfringens Type B Toxoid and Inactivated FMD (O) Virus with Adjuvant (ISA70-MF59)
1Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2Department of Research and Development, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
3Department of Microbiology, Faculty of Advanced Sciences, Islamic Azad University Tehran Medical Sciences, Tehran, Iran
4Department of Anaerobic Vaccine Research and Production, Specialized Clostridia Research Laboratory, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
5Department of Foot and Mouth Vaccine Production, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
چکیده
Foot and mouth disease (FMD) and enterotoxemia are important diseases of hoofed animals. Vaccination against livestock pathogens, especially these two diseases, plays a key role in the prevention and control of these diseases. The use of combined vaccines with the aim of creating a better immune response and producing cheaper vaccines is a great contribution to Vaccine industry. This research aimed to compare the immunogenicity of FMD (O) and Clostridium perfringens type B toxoid along with adjuvant (MF59) and Montanide (ISA70) to create the best immunogenicity. To investigate the immune responses of vaccines, it was injected into an animal model, and the antibody titer was measured by enzyme-linked immunosorbent assay (ELISA) test and VN antibody titer. The results showed that the formulation with MF59 adjuvant brought more stable immunogenicity against FMD and Clostridium perfringens type B, and the length of the immunogenicity period also increased significantly. Therefore, the combined vaccine (Clostridium perfringens + FMD) could play a major role invaccine industry as an alternative vaccine against Clostridium perfringens and FMD in livestock.
ارزیابی ایمنی زایی توکسوئید Clostridium perfringens type (B) و ویروس غیر فعال FMD(O) همراه با ادجوانت
(ISA70-MF59)
چکیده [English]
بیماری تب برفکی (FMD) و (آنتروتوکسمی) از بیماریهای مهم حیوانات سم دار می باشند. واکسیناسیون علیه پاتوژنهای دامی به ویژه این دو بیماری نقش مهمی در پیشگیری و کنترل دارد. استفاده از واکسن های ترکیبی(combination vaccine) با هدف ایجاد پاسخ ایمنی بهتر و تولید واکسن موثر و ارزانتر کمک بسیار مهمی به این صنعت است. این پروژه با هدف مقایسه ایمنی زایی ویروس FMD(O) و توکسوئید Clostridium perfringens type (B) همراه با ادجوانت ( MF59) وMontanide(ISA70) انجام گردید، تا بتواند ایمنی زایی مطلوب تری ایجاد نماید. لذا جهت بررسی پاسخهای ایمنی واکسن ها، به مدل حیوانی تزریق شدند و تیتر آنتی بادی با تست الایزا و VN antibody titer سنجیده شد. نتایج نشان داد که فرمولاسیون با ادجوانت MF59 ایمنی زایی بیشتر و پایدارتری بر علیه بیماری تب برفکی و Clostridium perfringens type (B) ایجاد نموده، و طول دوره ایمنی زایی نیز افزایش معنا داری می یابد. بنابراین، واکسن ترکیبی Clostridium perfringens - FMD می تواند در مقیاس صنعتی به عنوان یک واکسن جایگزین علیه Clostridium perfringens و FMD در دامها ایفای نقش کند.
Spickler AR, Roth JA. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med. 2003;17(3):273-81.
Tizard IR. Adjuvants and adjuvanticity. In: Tizard IR, editor. Vaccines for Veterinarians: Elsevier; 2021. p. 75-86.e1.
Ohtani K, Shimizu T. Regulation of Toxin Production in Clostridium perfringens. Toxins (Basel). 2016;8(7).
Pilehchian Langroudi R, Jabbari A, Moosawi Shoshtary M, Pardis A. A Production of pentavalent Clostridial toxoid vaccine and its comparison to conventional bacterin vaccine. Vet Res Biol Prod. 2015;28(1):34-42.
Khorasani A, Madadgar O, Soleimanjahi H, Keyvanfar H, Mahravani H. Evaluation of the efficacy of a new oil-based adjuvant ISA 61 VG FMD vaccine as a potential vaccine for cattle. Iran J Vet Res. 2016;17(1):8.
Zaragoza NE, Orellana CA, Moonen GA, Moutafis G, Marcellin E. Vaccine Production to Protect Animals Against Pathogenic Clostridia. Toxins (Basel). 2019;11(9).
Zayerzadeh E, Fardipour A, Jabbari AR. A new purification method for Beta-toxin of Clostridium perfringens type C Vaccinal strain. J Med Microbiol. 2014;3(3-4):8-13.
Ardehali M, Darakhshan H. Role of alum as adjuvant in Clostridial vaccines. Arch Razi Inst. 1979;31(1):9-15.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
Fathi Najafi M, Mashhadi M, Hemmaty M. Effectiveness of Chitosan Nanoparticles in Development of Pentavalent Clostridial Toxoid Vaccine in Terms of Clinical Pathology Elements and Immunological Responses. Arch Razi Inst. 2020;75(3):385-95.
Mahravani H. Evaluation of Foot and Mouth Disease virus concentration by cross flow system. Vet Res Biol Prod. 2019;32(1):17-23.
Gray AR, Wood BA, Henry E, Azhar M, King DP, Mioulet V. Evaluation of cell lines for the isolation of foot-and-mouth disease virus and other viruses causing vesicular disease. Front Vet Sci. 2020;7:426.
Tahir MF, Mahmood MS, Hussain I. Preparation and comparative evaluation of different adjuvanted toxoid vaccines against enterotoxaemia. Pak J agric Sci. 2013;50:293-7.
Paradise A, Abdolmohammadi Khiav L. Evaluation of epsilon antitoxin of Clostridium Perfringens type D in the rabbit serum by indirect ELISA. Vet Res Biol Prod. 2020;33(3):17-30.
Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev. 2004;17(2):465-93.
Rweyemamu MM, Booth JC, Parry N, Pay TW. Neutralization kinetics studies with type SAT 2 foot-and-mouth disease virus strains. J Hyg (Lond). 1977;78(3):429-38.
El-Bagoury G, El-Habbaa A, Gamil M, Fawzy H. Evaluation of an inactivated combined oil vaccine prepared for foot and mouth disease and bovine ephemeral fever viruses. Benha Vet Med J. 2014;27(1):221-31.
Lindblad EB, Duroux L. Mineral Adjuvants∗∗The present chapter is an updated version of the chapter “Mineral Adjuvants,” published in Immunopotentiators in Modern Vaccines, p. 217–233. Ed. Virgil Schijns & Derek O'Hagan, Elsevier Science Publishers (2005). In: Schijns VEJC, O'Hagan DT, editors. Immunopotentiators in Modern Vaccines (Second Edition): Academic Press; 2017. p. 347-75.
Yamanaka M, Okabe T, Nakai M, Goto N. Local pathological reactions and immune response of chickens to ISA-70 and other adjuvants containing Newcastle disease virus antigen. Avian Dis. 1993;37(2):459-66.
Ou H, Yao H, Yao W, Wu N, Wu X, Han C, et al. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice. Vaccine. 2016;34(20):2362-70.
Tariq M, Anjum AA, Sheikh AA, Awan AR, Ali MA, Sattar MMK, et al. Preparation and evaluation of alum precipitate and oil adjuvant multivalent vaccines against Clostridium perfringens. Kafkas Üniversitesi Veteriner Fakültesi Dergisi. 2021;27(4).